Immunotherapies targeting PD-1/PD-L1 have made great clinical progress in immune checkpoint therapy.[30–32] Elevated tumor mutation burden (TMB) or microsatellite instability (MSI) values have emerged as strong markers in predicting the immune checkpoint inhibitor (ICI) response.[33–35] The association between the JUN expression and immunotherapy-related biomarkers (TMB and MSI) was further explored. Here, JUN is linked to neoplasm.